2174264_eisai_logo

Eisai withdraws application for neurodegenerative-disease drug in Japan

pharmafile | March 22, 2016 | News story | Manufacturing and Production, Research and Development Eisai, mecobalamin, neurodegenerative disease 

Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat a neurodegenerative disease, citing insufficient information.

As a result the company has withdrawn its new drug application for mecobalamin, in Japan, following a meeting with the Pharmaceuticals and Medical Devices Agency (PMDA). Eisai said it will “carefully reconsider the future development strategy” for mecobalamin after consultation with the regulatory authority.

In May last year, Eisai filed for regulatory approval for mecobalamin as a treatment for amyotrophic lateral sclerosis (ALS).

Advertisement

ALS is an intractable, progressive, neurodegenerative disease that causes severe muscle atrophy and weakness in the muscles. Currently, there are limited treatment options for the disorder.

As the main cause of death is respiratory failure due to paralysis of the respiratory muscles, without the use of an artificial respirator, death occurs within about 3 and 6 years from the onset of the disease. In Japan, the incidence rate of ALS ranges between 1.1 to 2.5 per 100,000 people, and onset most often occurs between the ages of 50 to 60.

Mecobalamin is approved and marketed as a treatment for peripheral neuropathies and other conditions.

Anjali Shukla

Related Content

money_pills_2

EVerZom receives €3m funding from French government to industrialise exosome technology

EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m …

Roche advances treatment for Parkinson’s disease

Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …

handshake

Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases

Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development …

The Gateway to Local Adoption Series

Latest content